Board/Management Information • Jul 13, 2020
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 8578S
Hemogenyx Pharmaceuticals PLC
13 July 2020
13 July 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Grant of Options
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company ("Share Options") to certain PDMRs and a member of the Scientific Advisory Board of the Company.
The details of the Share Options granted are set out below:
| Name | Position | Number of Share Options Granted | Exercise Price (pence) | Vesting Date | Expiry Date |
| Peter Redmond | Non-Executive Director | 2,200,000 | 7 | Vesting in quarterly tranches over the 12 months from 13 July 2020 | 12 July 2025 |
| Andrew Wright | Financial Controller (PDMR) | 2,200,000 | 7 | 12 July 2025 | |
| Dr Alexander Tarakhovsky | Scientific Adviser | 1,800,626 | 3.5 | Immediate | 3 October 2022 |
Following the grant of the Share Options, in aggregate there will be 36,753,702 ordinary shares of 1p each of the Company under option to directors, employees and members of the Scientific Advisory Board of the Company, representing 8.48% of the issued ordinary share capital of the Company.
Enquiries:
| Hemogenyx Pharmaceuticals plc | www.hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | [email protected] |
| Peter Redmond, Director | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Soltan Tagiev | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow | |
| US Media enquiries | Tel: +1 (323) 646-3249 |
| Lowell Goodman | [email protected] |
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):
1.
Details of PDMR/person closely associated with them
a)
Name
1. Peter Redmond
2. Andrew Wright
b)
Position/status
1. Non-Executive Director
2. Financial Controller (PDMR, non-board)
c)
Initial notification/
amendment
Initial notification
2.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24
b)
Nature of the transaction
Grant of options
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 1. £0.07 2. £0.07 |
1. 2,200,000 2. 2,200,000 |
d)
Aggregated information
- Aggregated volume
- Price
| Price(s) | Volume(s) |
| N/A - variable | 4,400,000 |
e)
Date of the transaction
13/07/2020
f)
Place of the transaction
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHMZGMNDFDGGZM
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.